Log In Sign up
The largest database of trusted experimental protocols

Bp0061

Manufactured by BioXCell
Visit Supplier
Sourced in United States

The BP0061 is a laboratory centrifuge designed for general-purpose applications. It is a compact and versatile instrument capable of separating samples of various volumes and densities through the application of centrifugal force. The BP0061 features a user-friendly control panel and can operate at adjustable speeds to accommodate different experimental requirements.

Automatically generated - may contain errors

Lab products found in correlation

Bp0090, by BioXCell (2 mentions) Bp0003, by BioXCell (2 mentions) Bp0003 1, by BioXCell (2 mentions) Be0001 1, by BioXCell (1 mentions) Be0091, by BioXCell (1 mentions) Be0249, by BioXCell (1 mentions) Be0089, by BioXCell (1 mentions) Anti brdu antibody, by BioLegend (1 mentions) Be0146, by BioXCell (1 mentions) D0564 1mg, by Merck Group (1 mentions) Be0036, by BioXCell (1 mentions) Be0088, by BioXCell (1 mentions) Clone rb6 8c5, by BioXCell (1 mentions) Be0101, by BioXCell (1 mentions)

11 protocols using bp0061

1

Immune Checkpoint Modulation in Melanoma

Check if the same lab product or an alternative is used in the 5 most similar protocols
Anti-mouse CD3 (200 μg per mouse, Bio X Cell, BE0001-1) or anti-mouse CD8 (200 μg per mouse, Bio X Cell, BP0061) were injected (i.p.) three days before B16F10-mCherry-OVA inoculation (5 × 105 cells; i.d.) and continued every three days. Blood samples were taken twice weekly to confirm depletion, and tumour growth was measured daily.
Balood M., Ahmadi M., Eichwald T., Ahmadi A., Majdoubi A., Roversi K., Roversi K., Lucido C.T., Restaino A.C., Huang S., Ji L., Huang K.C., Semerena E., Thomas S.C., Trevino A.E., Merrison H., Parrin A., Doyle B., Vermeer D.W., Spanos W.C., Williamson C.S., Seehus C.R., Foster S.L., Dai H., Shu C.J., Rangachari M., Thibodeau J., V. Del Rincon S., Drapkin R., Rafei M., Ghasemlou N., Vermeer P.D., Woolf C.J, & Talbot S. (2022). Nociceptor neurons affect cancer immunosurveillance. Nature, 611(7935), 405-412.
+ Open protocol
+ Expand
2

Murine pancreatic cancer model and CXCR3 inhibition

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
Ptf1a/p48cre/+ and LSL-KrasG12D/+ mouse strains and genotyping of mice have been described previously (Liou et al., 2015 (link)). Seven to 8 week old Ptf1a/p48cre;LSL-KrasG12D (KC) or non-transgenic (ntg) mice with the same background were injected intraperitoneally (IP) with a CXCR3 neutralizing antibody (CXCR3 NAB; BE0249) (Bio X Cell, West Lebanon, NH) or an isotype control IgG; BE0091 (Bio X Cell) at 200 µg/mouse for 9 weeks. Males and females were randomly allocated to different groups since there are no sex-based differences observed in this model. All animal experiments were conducted under IACUC-approved protocols (A50214-14-R17, A30615-15-R18) and were run in accordance with institutional guidance and regulation.
For T-cell depletion, 6 week old Ptf1a/p48cre;LSL-KrasG12D mice were intraperitoneally injected with both anti-mouse CD4 (BP0003, Bio X Cell) and anti-mouse CD8α (BP0061, Bio X Cell) antibodies, or their IgG2b isotype control (BP0090, Bio X Cell). Two hundred micrograms of each antibody was injected per mouse for five consecutive days. After T-cell depletion, mice were segregated into different groups and injected with CXCR3 NAB (BE0249, Bio X Cell) or IgG isotype control antibodies (BE0091, Bio X Cell).
Pandey V., Fleming-Martinez A., Bastea L., Doeppler H.R., Eisenhauer J., Le T., Edenfield B, & Storz P. (2021). CXCL10/CXCR3 signaling contributes to an inflammatory microenvironment and its blockade enhances progression of murine pancreatic precancerous lesions. eLife, 10, e60646.
+ Open protocol
+ Expand
3

Therapeutic Evaluation of BAY1082439 in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
BAY1082439 was dissolved in 0.1 N HCL at 18 mg/ml and orally administered. For Single bullet treatment, BAY1082439 was administered at a dose of 180 mg/kg/d and mice were analyzed 24 h later. For daily treatment, BAY1082439 was administered at a dose of 75 mg/kg/d for 4 weeks. For intermittent treatment, BAY1082439 was administered at a dose of 180 mg/kg/d in a 2 days on/5 days off manner for 4 weeks. S1PR modulator (Fingolimod, FTY720) was dissolved in 0.9% NaCl saline solution and orally administered at 1 mg/kg/d. Anti-PD-1 (BioXcell, BE0146) or isotype control (BioXcell, BE0089) antibody (200ug per mice) was dosed 3 times per week by i.p. Anti-CD8 (BioXcell, BP0061) antibody (200ug per mice) was dosed 3 times per week by i.p. BrdU was dissolved in PBS at 10 mg/ml and dosed 100 mg/kg by i.p 24 h before analysis. BrdU positive cells were analyzed by Flow Cytometry using eBioscience™ BrdU Staining Buffer Set (00-5525-00) and anti-BrdU antibody (Biolegend 339812 1:100).
Qi Z., Xu Z., Zhang L., Zou Y., Li J., Yan W., Li C., Liu N, & Wu H. (2022). Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment. Nature Communications, 13, 182.
+ Open protocol
+ Expand
4

Depletion and Blockade Strategies for Studying Immune Cell Roles

Cited 2 times
Check if the same lab product or an alternative is used in the 5 most similar protocols
For DT-mediated depletion of KCs, Clec4fcreRosa26LSL-DTR mice and Rosa26LSL-DTR mice were intraperitoneally injected with 100 ng DT (D0564-1MG, Sigma-Aldrich) as a single dose or weekly injections25 (link), as indicated in the figure legends for the corresponding experiments. The efficiency of KC depletion was determined in Extended Data Fig. 1j.
For CSF1R inhibitor treatment with PLX562231 , C57BL/6J mice were fed ad libitum with PLX5622-impregnated chow (1,200 mg per kg, provided by Plexxicon) or control chow 2 weeks before injection of tumour cells.
For the SIRPA blockage assay, Clec4fcreId3f/f mice and Id3f/f littermates were intraperitoneally injected with control IgG (HRPN, BioXcell) or 250 μg anti-SIRPA (P84, BioXcell) 2 days before and every 2 days after tumour cell injection.
For phosphatidylserine blockade80 (link), C57BL/6J mice were injected i.v. with PBS or 1 μg MFG-E8(D89E)81 (link) (gift from S. Nagata), 6 h before injection of tumour cells.
For NK cell and CD8 T cell depletion, 8–12-week-old Clec4fcreId3f/f mice and Id3f/f littermates were intraperitoneally injected with control IgG (HRPN, BioXcell), or 200 μg anti-NK1.1 (BE0036, BioXcell) and 200 μg anti-CD8 (BP0061, BioXcell) 1 day before tumour injection and every 4 days afterwards.
Deng Z., Loyher P.L., Lazarov T., Li L., Shen Z., Bhinder B., Yang H., Zhong Y., Alberdi A., Massague J., Sun J.C., Benezra R., Glass C.K., Elemento O., Iacobuzio-Donahue C.A, & Geissmann F. (2024). The nuclear factor ID3 endows macrophages with a potent anti-tumour activity. Nature, 626(8000), 864-873.
+ Open protocol
+ Expand
5

Anti-FAP Photodynamic Therapy in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
MC38 (0.5 × 106 cells) with and without MEF (0.5 × 106 cells) were suspended in PBS (150 μL) and injected subcutaneously into the right flank of 6-week-old female BALB/c-nu/nu and C57BL/6 mice. To evaluate tumor growth, the diameter of each tumor was measured every 3 days. Tumor volume (mm3) was calculated using the formula: length × width2 × 0.5. The treatment mice were randomized and injected with 50 μg/body of anti-FAP conjugated IR700 intraperitoneally when tumors reached 50–100 mm3. On the next two days, the tumors were irradiated with NIR light at 50 J/cm2 (150 mW/cm2).
For T-cell depletion studies, anti-CD8α antibodies (BP0061; BioXcell, New Hampshire, USA) and anti-CD4 antibodies (BP0003; BioXcell) were injected intraperitoneally at 10 mg/kg per day before the first injection of APC, and every 3 days thereafter, for a total of four treatment rounds. The animals were euthanized via CO2, and serum and tumor tissue were collected for further analyses.
Akai M., Noma K., Kato T., Nishimura S., Matsumoto H., Kawasaki K., Kunitomo T., Kobayashi T., Nishiwaki N., Kashima H., Kikuchi S., Ohara T., Tazawa H., Choyke P.L., Kobayashi H, & Fujiwara T. (2024). Fibroblast activation protein-targeted near-infrared photoimmunotherapy depletes immunosuppressive cancer-associated fibroblasts and remodels local tumor immunity. British Journal of Cancer, 130(10), 1647-1658.
+ Open protocol
+ Expand
6

Investigating Tumor Growth Inhibition by MR16-1

Check if the same lab product or an alternative is used in the 5 most similar protocols
Colon26 (0.5 × 106) cells with and without NIH/3T3 (0.5 × 106) cells were subcutaneously inoculated into the right flank of 6-week-old female BALB/c mice. The perpendicular diameter of each tumor was measured every 3 days. Tumor volume was calculated using the formula: Tumor volumemm3=L×W2×0.5
L represents the longest diameter, W represents the shortest diameter, and 0.5 is a constant used to calculate the volume of an ellipsoid. Treatment with intraperitoneal injections of 20 mg/kg of isotype control (BE0088; BioXcell, Lebanon, NH, USA) or MR16-1 every 3 days began when tumors reached 50–100 mm3. To generate other cancer models, Pan02 and MEF models were established in C57BL/6 mice, while SCCVII and MEF models were established in C3H/He mice, which were then inoculated and treated in the same way as the Colon26 model.
For T-cell depletion studies, anti-CD8α antibodies (BP0061; BioXcell) were injected intraperitoneally at 10 mg/kg per day before the first injection of isotype control or MR16-1, and every 3 days thereafter, for a total of four treatments. The animals were euthanized via cervical dislocation, and serum and tumor tissue were collected for further analyses.
Nishiwaki N., Noma K., Ohara T., Kunitomo T., Kawasaki K., Akai M., Kobayashi T., Narusaka T., Kashima H., Sato H., Komoto S., Kato T., Maeda N., Kikuchi S., Tanabe S., Tazawa H., Shirakawa Y, & Fujiwara T. (2023). Overcoming cancer-associated fibroblast-induced immunosuppression by anti-interleukin-6 receptor antibody. Cancer Immunology, Immunotherapy, 72(7), 2029-2044.
+ Open protocol
+ Expand
7

Depletion of CD4+ and CD8+ T cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
For the depletion of CD4+ and CD8+ T cells, mice were i.p. injected with 500μg anti-CD4 (BioXCell, BP0003–1) and anti-CD8 antibody (BioXCell, BP0061) every 5 days from 6 to 9.5 months of age or for memory related behavioral experiments from 6 to 8.5 months of age. IgG (BioXCell, BP0090) isotype control was administered at the same frequency and dosage. To characterize the depletion efficiency, mice were acutely treated with 500 μg anti-CD4, or anti-CD8 or IgG. Brain, meninges and blood were extracted for single cell analysis followed by flow cytometry assessment of CD4+ and CD8+ T cell populations.
Chen X., Firulyova M., Manis M., Herz J., Smirnov I., Aladyeva E., Wang C., Bao X., Finn M.B., Hu H., Shchukina I., Kim M.W., Yuede C.M., Kipnis J., Artyomov M.N., Ulrich J.D, & Holtzman D.M. (2023). Microglia-mediated T cell Infiltration Drives Neurodegeneration in Tauopathy. Nature, 615(7953), 668-677.
+ Open protocol
+ Expand
8

Depletion of Immune Cells and MDSC in Tumor-Bearing Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
For cell depletion studies, mice were randomized at 50mm3 tumor volume and injected with 100 μL antibodies through the intraperitoneal route. An initial depletion with 400 μg of anti-CD8a antibody (Cat: BP0061, clone 2.43, BioXcell) or rat IgG2b isotype control (Cat: BE0090, BioXcell) was administered on days 7, 11, and 15 post-tumor inoculation. Antibody depletion treatment was continued with the administration of 400 μg of antibody every 3-5 days for the duration of the experiment. For depletion of MDSCs, ~1w post tumor inoculation, mice with palpable tumors were injected intraperitoneally (IP) with anti-GR1 antibody 200 μg/dose (Cat: BE0075, clone RB6-8C5, BioXcell) or isotype IgG2b (Cat: BE0090, BioXcell) every 48 hours. On Day 18 after the first anti-GR1 antibody administration, the lungs were harvested to evaluate for metastasis. Tumors & other organs were also harvested to confirm the depletion of MDSC. Depletion efficiency was checked using FACS analysis of blood obtained by retro-orbital bleeding. For conditioned media treatment, concentrated CM from WT-Gal1 or KO-Gal1 cells or similarly concentrated control media was used. When tumors reached ~100mm3 in size, 100μl of CM/control media was injected IP every other day for ~3 weeks until termination.
Rørvik L.M., Aase B., Alvestad T, & Caugant D.A. (2000). Molecular Epidemiological Survey of Listeria monocytogenes in Seafoods and Seafood-Processing Plants. Applied and Environmental Microbiology, 66(11), 4779-4784.
+ Open protocol
+ Expand
9

CD8+ T Cell Depletion in KPC Tumor Model

Check if the same lab product or an alternative is used in the 5 most similar protocols
CD8 + T cells were depleted by intraperitoneal injection (i.p.) of anti-CD8 monoclonal antibodies (mAbs) (BP0061, Bio X Cell, 200 μg per mouse) 3 days in advance of KPC tumor cell (5 × 105) orthotopic inoculation. αCD8 was given every three days throughout the experiment.
Yang H., Zhang X., Lao M., Sun K., He L., Xu J., Duan Y., Chen Y., Ying H., Li M., Guo C., Lu Q., Wang S., Su W., Liang T, & Bai X. (2022). Targeting ubiquitin-specific protease 8 sensitizes anti-programmed death-ligand 1 immunotherapy of pancreatic cancer. Cell Death and Differentiation, 30(2), 560-575.
+ Open protocol
+ Expand
10

Xenograft Models for Cancer Research

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
Xenograft models have been described in detail previously [29 (link)]. Briefly, the mice were randomly divided into the indicated groups. Tumor volume was assessed at regular intervals of three days using the formula V = L × W2/2. In the case of RT, the nude mice were subjected to a single dose of 10 Gy, while the C57BL/6J mice received three fractions of 8 Gy each. In the CDKL1-overexpressing group, nude mice were injected with 5 × 106 A549 stable cells, whereas C57/BL6J mice were injected with 8 × 105 Lewis stable cells. To block PD-L1 expression and CD8+ T cell activation, an anti-PD-L1 antibody (BioXcell, BE0101) or anti-CD8+ T-cell antibody (BioXcell, BP0061) was administered via injection every four days.
Li Z., Xue H., Li J., Zheng Z., Liu Z., Dong X., Wang H., Chen J, & Xu S. (2024). CDKL1 potentiates the antitumor efficacy of radioimmunotherapy by binding to transcription factor YBX1 and blocking PD-L1 expression in lung cancer. Journal of Experimental & Clinical Cancer Research : CR, 43, 89.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!